{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=8&q=ALK",
    "query": {
      "q": "ALK",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 310,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=9&q=ALK&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=7&q=ALK&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:09:58.504Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04634110",
      "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Metastases",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-11-17",
      "completion_date": "2022-04-14",
      "has_results": true,
      "last_update_posted_date": "2022-10-24",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Aurora, Colorado • Rochester, Minnesota",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634110"
    },
    {
      "nct_id": "NCT04900935",
      "title": "Patient-centered, Optimal Integration of Survivorship and Palliative Care",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage IV Non-small Cell Lung Cancer",
        "Targeted Therapy",
        "Nonsmall Cell Lung Cancer",
        "Carcinoma, Non-Small-Cell Lung",
        "ALK-positive Non-small Cell Lung Cancer",
        "EGFR Positive Non-small Cell Lung Cancer",
        "Palliative Care",
        "Survivorship"
      ],
      "interventions": [
        {
          "name": "POISE",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2023-09-29",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04900935"
    },
    {
      "nct_id": "NCT03052608",
      "title": "A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 296,
      "start_date": "2017-04-27",
      "completion_date": "2028-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 34,
      "location_summary": "Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03052608"
    },
    {
      "nct_id": "NCT03456063",
      "title": "A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 453,
      "start_date": "2018-04-24",
      "completion_date": "2025-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03456063"
    },
    {
      "nct_id": "NCT02552901",
      "title": "Cardiox Liver Function Test Pivotal Trial",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatic Failure",
        "Liver Failure"
      ],
      "interventions": [
        {
          "name": "0.1 mg/kg ICG Dose",
          "type": "DRUG"
        },
        {
          "name": "0.5 mg/kg ICG dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cardiox Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-11",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-01-15",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02552901"
    },
    {
      "nct_id": "NCT03868423",
      "title": "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "ALK Fusion Protein Expression",
        "ALK Gene Amplification",
        "ALK Gene Mutation",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Metastatic Malignant Solid Neoplasm",
        "ROS1 Fusion Positive",
        "ROS1 Gene Amplification",
        "ROS1 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sameek Roychowdhury",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-03-20",
      "completion_date": "2021-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03868423"
    },
    {
      "nct_id": "NCT00082017",
      "title": "UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Large-Cell, Ki-1",
        "Lymphoma, T-Cell"
      ],
      "interventions": [
        {
          "name": "UCN-01 (7-hydroxystaurosporine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-04-05",
      "completion_date": "2011-09-27",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082017"
    },
    {
      "nct_id": "NCT07729397",
      "title": "Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Hodgkin Lymphoma",
        "Peripheral T-cell Lymphoma (PTCL)",
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Anaplastic Large Cell Lymphoma, ALK-Negative"
      ],
      "interventions": [
        {
          "name": "Autologous C7R.CD30-CAR-EBVSTs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2027-01-15",
      "completion_date": "2044-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07729397"
    },
    {
      "nct_id": "NCT03310281",
      "title": "Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "HOLD: Videogame",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Akili Interactive Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 84,
      "start_date": "2017-12-04",
      "completion_date": "2018-11-14",
      "has_results": false,
      "last_update_posted_date": "2018-11-21",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 4,
      "location_summary": "Garden Grove, California • North Miami, Florida • Charleston, North Carolina",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "North Miami",
          "state": "Florida"
        },
        {
          "city": "North Miami",
          "state": "Florida"
        },
        {
          "city": "Charleston",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03310281"
    },
    {
      "nct_id": "NCT03386929",
      "title": "Survival Prolongation by Rationale Innovative Genomics",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer Metastatic",
        "Non-small Cell Lung Cancer Stage IIIB"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Worldwide Innovative Network Association",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-11-29",
      "completion_date": "2022-12-29",
      "has_results": true,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-11-15T12:09:58.504Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386929"
    }
  ]
}